Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) was initiated in the first year of the Innovative Medicines Initiative (IMI). It was an ambitious plan to tackle the understanding of asthma through an integration of clinical and multi-’omics approaches that necessitated the bringing together of industry, academic, and patient representatives because it was too large to be managed by any one of the partners in isolation. It was a novel experience for all concerned. In this review, we describe the main features of the U-BIOPRED experience from the industry perspective. We list some of the key advantages and learnings from the perspective of the authors, and also improvements that we feel could be made in future projects.

在创新药物倡议（IMI）的第一年，就开始了无偏见的生物标志物用于呼吸道疾病预后的预测（U-BIOPRED）。这是一项雄心勃勃的计划，需要通过临床和多组学方法的整合来解决对哮喘的认识，这需要将行业代表，学术代表和患者代表召集在一起，因为它太大了，无法由任何一个合作伙伴进行管理。隔离。对于所有相关人员而言，这是一次新颖的经历。在这篇评论中，我们从行业角度描述了U-BIOPRED体验的主要特征。我们从作者的角度列出了一些关键的优势和经验教训，以及我们认为可以在将来的项目中进行改进的方面。